Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EHA 2020 | Identifying high-risk AML

Jeffrey Lancet • 8 Jun 2020
EHA 2020
Acute Myeloid Leukemia Leukemia

Jeffrey Lancet, MD, of H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, discusses the identification of high-risk acute myeloid leukemia (AML). This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Jeffrey Lancet

Canakinumab with darbepoetin in patients with LR-MDS who are ESA-refractory 4:48
Canakinumab with darbepoetin in patients with LR-MDS who are ESA-refractory
Jeffrey Lancet • 8 Dec 2023
COVALENT-101: investigating menin inhibition with BMF-219 for treating patients with R/R AML or ALL 5:17
COVALENT-101: investigating menin inhibition with BMF-219 for treating patients with R/R AML or ALL
Jeffrey Lancet • 8 Dec 2023
The impact of secondary-type mutations in NPM1-mutated AML 1:45
The impact of secondary-type mutations in NPM1-mutated AML
Jeffrey Lancet • 11 Dec 2021
Responses to COVID-19 vaccines in patients with AML and MDS 6:57
Responses to COVID-19 vaccines in patients with AML and MDS
Jeffrey Lancet • 11 Dec 2021

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals